Planta Medica International Open 2017; 4(S 01): S1-S202
DOI: 10.1055/s-0037-1608472
Poster Session
Georg Thieme Verlag KG Stuttgart · New York

Gastroprotective effects of HT074, combined extracts of Inula britannica and Paeonia lactiflora on experimental gastric ulcer models in Sprague-Dawley rats

YS Kim
1   Department of Herbal Pharmacology, College of Korean Medicine, Kyung Hee University, Seoul, Korea, Republic of (South)
,
J Song
1   Department of Herbal Pharmacology, College of Korean Medicine, Kyung Hee University, Seoul, Korea, Republic of (South)
,
D Lee
1   Department of Herbal Pharmacology, College of Korean Medicine, Kyung Hee University, Seoul, Korea, Republic of (South)
,
J Park Hyo
2   Korea Institute of Science and Technology for Eastern Medicine (KISTEM), NeuMed Inc, Seoul, Korea, Republic of (South)
,
K Kim Dong
2   Korea Institute of Science and Technology for Eastern Medicine (KISTEM), NeuMed Inc, Seoul, Korea, Republic of (South)
,
H Kim
1   Department of Herbal Pharmacology, College of Korean Medicine, Kyung Hee University, Seoul, Korea, Republic of (South)
› Author Affiliations
Further Information

Publication History

Publication Date:
24 October 2017 (online)

 

The herbal formula HT074 is combined extracts of Inula britannica flower and Paeonia lactiflora root. In traditional Korean medicine, the flower of I. britannica have been prescribed for the treatment of digestive disorders and inflammation. The root of P. lactiflora has been used for enhancing blood circulation and inhibiting inflammation. This study aimed to investigate the gastroprotective effects of HT074 in three different acute gastric ulcer rat models and to elucidate the potential protective mechanism.

Gastric lesions were induced in seven-week-old Sprague-Dawley rats by acidified ethanol (HCl/EtOH), indomethacin, and water-immersion and restraint-stress. In each experiment, rats were randomly divided into 5 groups: vehicle control, omeprazole 20 mg/kg (positive control), HT074 30, 100, and 300 mg/kg. The gastric lesion area was measured by imageJ (National Institutes of Health, Bethesda, MD) program. Adhered gastric mucus was estimated by alcian blue binding assay.

We found that HT074 conferred profound gastric protection in three different models. In HCl/EtOH-induced gastric ulcer model, HT074 300 mg/kg administered orally at 30 minutes prior to inducer significantly reduced the gastric lesion by 99.0% compared to control. In indomethacin-induced gastric ulcer model, HT074 300 mg/kg administered orally at 30 minutes prior to inducer significantly reduced the gastric lesion by 78.5% compared to control. In the water-immersion and restraint-stress-induced gastric ulcer model, HT074 300 mg/kg administered orally at 1 hour prior to water-immersion significantly reduced the gastric lesion by 81.5% compared to control. Furthermore, the treatment with HT074 increased gastric mucus dose-dependently in HCl/EtOH induced gastric ulcer model.

In conclusion, these results suggest that HT074 inhibits the gastric lesion development by stimulating mucus secretion. HT074 could be helpful for preventing gastritis and gastric ulcer.